Clinical Trials
32 trialsLEADER
Takeda
Biomarker for Infection Risk in CLL and MM
Massachusetts General Hospital
MUST
Pfizer
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Agriculture Health Study
National Institutes of Health Clinical Center (CC)
RHUMM
Intergroupe Francophone du Myelome
TEC-CARE
Intergroupe Francophone du Myelome
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
Memorial Sloan Kettering Cancer Center
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
M.D. Anderson Cancer Center
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Memorial Sloan Kettering Cancer Center
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
SEATTLE
iOMEDICO AG
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
Takeda
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Bristol-Myers Squibb
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
Pfizer
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Pfizer
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
City of Hope Medical Center
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
All4Cure
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
Tel-Aviv Sourasky Medical Center
M4
Horizon Health Network
IONA-MM
Sanofi
CLARITY
Gruppo Italiano Malattie EMatologiche dell'Adulto
MMRF Molecular Profiling Protocol
Multiple Myeloma Research Foundation
Selinexor
Durham VA Medical Center
OxPLoreD
University of Oxford
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Alliance for Clinical Trials in Oncology
HemaTMA
Tampere University Hospital
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
The First Affiliated Hospital of Soochow University
ABE-DESCART
Bristol-Myers Squibb